Results 141 to 150 of about 30,927 (236)

The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein

, 2016
Claudia Walliser, Elisabeth Hermkes, Anja Schade, Sebastian Wiese, Julia Deinzer, Marc Zapatka, Laurent Désiré, Daniel Mertens, Stephan Stilgenbauer, Peter Gierschik   +9 more
openalex   +1 more source

CHEMO‐FREE TRIPLET COMBINATION OF TGR‐1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL. [PDF]

, 2017
Loretta J. Nastoupil, Matthew A. Lunning, Julie M. Vose, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Jan A. Burger, William G. Wierda, Susan O’Brien, Peter Sportelli, Hari P. Miskin, Michelle Purdom, Michael Weiss, Nathan Fowler   +14 more
openalex   +1 more source

Efficacy, Toxicity and Effect of Pretreatment Cardiologic Consultation on Outcomes of Ibrutinib Therapy for Chronic Lymphocytic Leukemia-A KroHem Study. [PDF]

Cancers (Basel)
Mandac Smoljanović I, Aurer I, Bulj N, Dreta B, Miljak A, Petričević F, Ivić M, Bašić-Kinda S, Zatezalo V, Madunić S, Čaržavec D, Sinčić-Petričević J, Grohovac D, Jakšić O, Krečak I, Morić-Perić M, Coha B, Berneš P, Živković N, Pejša V.   +19 more
europepmc   +1 more source

Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017 [PDF]

, 2017
Stefano Molica
openalex   +1 more source

Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL. [PDF]

Blood Adv
Allan JN, Ran T, Ding Z, He J, Bokun A, Qureshi ZP, O'Brien SM.   +6 more
europepmc   +1 more source

Safety and efficacy of single-agent ibrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): A multicenter, open-label, phase 2 study [PDF]

, 2017
Graham P. Collins, Ariela Noy, Sven de Vos, Catherine Thiéblemont, Peter Martin, Christopher R. Flowers, Franck Morschhauser, Shuo Ma, Morton Coleman, Shachar Peles, Stephen D. Smith, Jacqueline C. Barrientos, Ashley M. Smith, Brian Munneke, Isaiah W. Dimery, Darrin M. Beaupre, R. Chen   +16 more
openalex   +1 more source

Elucidating novel immune profiles for predicting infection in high-risk cohorts: a pilot study in patients with relapsed and refractory chronic lymphocytic leukaemia. [PDF]

Clin Transl Immunology
Williams LJ, Li-Wai-Suen CS, Garnham AL, Bader SM, Tam CS, Whitechurch A, Slavin MA, Doerflinger M, Teh BW.   +8 more
europepmc   +1 more source

PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB VERSUS PLACEBO IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH TREATMENT‐NAÏVE FOLLICULAR LYMPHOMA (PERSPECTIVE) [PDF]

, 2017
S. Rule, Ian W. Flinn, Nathan Fowler, R. Chen, Long Kwei, Darrin M. Beaupre, Alvina D. Chu, Leo I. Gordon   +7 more
openalex   +1 more source

Pharmacogenetic Biomarkers of Ibrutinib Response and Toxicity in Chronic Lymphocytic Leukemia: Insights from an Observational Study. [PDF]

Pharmaceuticals (Basel)
Pérez-Gómez N, Sanz-Solas A, Cuevas B, Cuevas MV, Alonso-Madrigal C, Loscertales J, Álvarez-Nuño R, García C, Zubiaur P, Villapalos-García G, Parra-Garcés RM, Mejía-Abril G, Alcaraz R, Vinuesa R, Díaz-Gálvez FJ, González-Oter M, García-Sancha N, Azibeiro-Melchor R, González-López TJ, Abad-Santos F, Labrador J, Saiz-Rodríguez M.   +21 more
europepmc   +1 more source

Bruton’s tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia [PDF]

, 2018
AG Evans, B Mizukawa, FM Vega, G Pillinger, H Wu, HP Kuo, HS Kuehn, J Wei, K Bence, L Zaitseva, M Konopleva, MA Ayoub, MY Murray, R Schrage, S Tavor, SA Rushworth, SP Xu, T Oellerich, TL Gu   +18 more
core   +1 more source